U.S. Markets closed
  • S&P Futures

    4,407.75
    -6.50 (-0.15%)
     
  • Dow Futures

    34,982.00
    -52.00 (-0.15%)
     
  • Nasdaq Futures

    15,098.50
    -19.25 (-0.13%)
     
  • Russell 2000 Futures

    2,208.30
    -5.10 (-0.23%)
     
  • Crude Oil

    72.18
    +0.27 (+0.38%)
     
  • Gold

    1,798.70
    -0.50 (-0.03%)
     
  • Silver

    25.24
    -0.08 (-0.31%)
     
  • EUR/USD

    1.1808
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • Vix

    17.58
    +0.38 (+2.21%)
     
  • GBP/USD

    1.3826
    +0.0002 (+0.0180%)
     
  • USD/JPY

    110.1800
    -0.1950 (-0.1767%)
     
  • BTC-USD

    36,766.53
    -1,438.03 (-3.76%)
     
  • CMC Crypto 200

    870.60
    -44.89 (-4.90%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,932.08
    +98.79 (+0.35%)
     

Amgen Pays $1.9B For Five Prime Therapeutics Acquisition

·2 min read

Amgen Inc (NASDAQ: AMGNhas agreed to acquire Five Prime Therapeutics Inc (NASDAQ: FPRX) for $38 per share in cash, representing an equity value of approximately $1.9 billion.

  • The offer price of $38 represents a whopping 79% premium on the last close price of $21.26 on Wednesday.

  • Five Prime's immuno-oncology and targeted cancer therapies pipeline include five programs. Lead asset bemarituzumab is a Phase 3 ready anti-FGFR2b antibody.

  • In January, the company reported positive Phase 2 data in frontline advanced gastric or gastroesophageal junction cancer, demonstrated clinically meaningful improvements in progression-free survival, overall survival, and overall response rate.

  • Amgen says that the FPRX acquisition offers a compelling opportunity to strengthen its oncology portfolio with a promising late-stage asset to treat gastric cancer.

  • Amgen plans to leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumab's potential.

  • As part of this transaction, Amgen will receive a royalty percentage on future net sales in Greater China, ranging from the high teens to the low twenties, from a pre-existing co-development and commercialization agreement between Five Prime and Zai Lab Ltd (NASDAQ: ZLAB).

  • Amgen reaffirmed its full-year outlook with Revenue guidance of $25.8 to $26.6 billion and non-GAAP EPS guidance of $16.00-$17.00.

  • Goldman Sachs acted as financial advisor to Amgen and Sullivan & Cromwell LLP as its legal advisor. Lazard acted as financial advisor to Five Prime and Cooley LLP as its legal advisor.

  • Amgen will host an investor call at 10:30 a.m. ET today.

  • Price Action: FPRX shares are trading higher by 78.1% at $37.86, while AMGN shares gained 1.49% at $227.27 on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.